Athersys: An Ischemic Stroke Holy Grail? Find Out In Less Than A Month

Athersys is a development stage biotech that fully enrolled a Phase 2 stem cell trial for ischemic stroke at the end of 2014. Results will likely be a binary event: company crippling or validating MultiStem for ischemic stroke and many other significant indications.

http://ift.tt/1IrYNqa